Future directions for temozolomide therapy

Seminars in Oncology

Volumn 28, Issue 4 SUPPL. 13, 2001, Pages 43-46

  Yung, W K Alfred ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; ASTROCYTOMA; BRAIN METASTASIS; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EUROPE; GLIOBLASTOMA; HUMAN; MELANOMA; PRIORITY JOURNAL; REVIEW; UNITED STATES;

EID: 0034820950     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.26652     Document Type: Review

References (16)

1. NMR and molecular modeling investigation of the mechanism of action of the antitumor drug temozolomide and its interaction with DNA
2. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)
3. Demonstration and quantitation of temozolomide uptake in vivo in human brain tumors
4. Cerebrospinal fluid levels of temozolomide as a surrogate marker of brain penetration
5. O6-Methylguanine-DNA methyltransferase in pretreatment turnout biopsies as a predictor of response to temozolomide in melanoma
6. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl) nitrosourea
7. Methylator resistance mediated by mismatching repair deficiency in glioblastoma multiforme xenograft
8. In vivo administration of O(6)-benzylguanine does not influence apoptosis or mutation frequency following DNA damage in the murine intestine, but does inhibit P450-dependent activation of dacarbazine
9. Inhibition of DNA repair as a means of increasing the antitumor activity of DNA reactive agents
10. Phase I trial of temozolomide using an extended continuous oral schedule
11. Phase I-II study with continuous dose-escalated 21-day schedule temozolomide in recurrent high-grade glioma
12. Protracted daily administration of temozolomide is feasible. A phase I pharmacokinetic/pharmacodynamic study
13. Protracted cyclic administration of temozolomide is feasible. A phase 1 pharmacokinetic and pharmacodynamic study
14. A phase I and pharmacokinetic (PK) trial of 2 sequences of BCNU and temozolomide (TMZ) in patients with advanced solid tumors
15. Combined immunotherapy with GM-CSF, IL-2, and IFNα allows dose escalation of temozolomide with prevention of lymphocytopenia and brain metastases in metastatic malignant melanoma
16. A multicenter phase II study of modified biochemotherapy (BCT) for stage IV melanoma incorporating temozolomide, decrescendo interleukin-2 (IL-2), and GM-CSF